The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
GlobalData on MSN23h
EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s diseaseFollowing a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
The EU's drugs regulator recommends approval of Eisai and Biogen's Alzheimer's drug, Leqembi, for patients with early stages ...
After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback